Verastem (VSTM) Projected to Post Earnings on Thursday

Verastem (NASDAQ:VSTM) is projected to issue its Q1 2025 quarterly earnings data before the market opens on Thursday, May 8th. Analysts expect Verastem to post earnings of ($0.65) per share and revenue of $0.10 million for the quarter.

Verastem (NASDAQ:VSTM) last released its quarterly earnings results on Thursday, March 20th. The biopharmaceutical company reported ($1.33) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.57). On average, analysts expect Verastem to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Verastem Price Performance

Shares of VSTM stock opened at $7.01 on Tuesday. The company has a current ratio of 3.23, a quick ratio of 3.23 and a debt-to-equity ratio of 2.77. The firm has a market capitalization of $360.94 million, a price-to-earnings ratio of -2.20 and a beta of 0.57. The firm’s 50 day moving average is $6.26 and its 200-day moving average is $5.38. Verastem has a 1 year low of $2.10 and a 1 year high of $13.52.

Analyst Ratings Changes

A number of research analysts have commented on VSTM shares. Guggenheim increased their price objective on Verastem from $13.00 to $14.00 and gave the company a “buy” rating in a research report on Monday, March 24th. Royal Bank of Canada dropped their price objective on Verastem from $16.00 to $14.00 and set an “outperform” rating for the company in a report on Friday, March 21st. HC Wainwright raised their target price on shares of Verastem from $7.00 to $10.00 and gave the company a “buy” rating in a research note on Monday, March 24th. StockNews.com cut shares of Verastem from a “hold” rating to a “sell” rating in a research report on Friday, April 18th. Finally, Jefferies Financial Group initiated coverage on shares of Verastem in a report on Thursday, April 10th. They issued a “buy” rating and a $15.00 price objective on the stock. One research analyst has rated the stock with a sell rating and ten have assigned a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $13.89.

About Verastem

Verastem, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors.